Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.
| 4.48 | |
| 4.5 | |
| - | |
| 4.54 | |
| 4.38 | |
| 1.111-6.72 | |
| 504 M | |
| 113 M | |
| 5 347 K | |
| -0.22 | |
| 2.204 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
It’s no secret that artificial intelligence (AI) promises to transform every industry and sector, pharma included. But how do those companies plan to leverage AI, and what will it do for their stoc...
In this article, we will take a detailed look at the 11 Stocks Insiders are Buying Now. For a quick overview of such stocks, read our article 5 Stocks Insiders are Buying Now. Despite a hotter-than-e...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
